Literature DB >> 12820346

Expression of tumor markers on breast and ovarian cancer cell lines.

Ulrike Kämmerer1, Florian Thanner, Michaela Kapp, Johannes Dietl, Marc Sütterlin.   

Abstract

BACKGROUND: Breast and ovarian tumor cell lines with defined tumor-associated antigens could serve as allogeneic antigen-sources for the biological therapy of cancer.
MATERIALS AND METHODS: Eight breast and 3 ovarian cancer cell lines were stained for the antigens in question by immunohistochemistry. Antigen-expression was graded in 5 steps by light microscopic examination.
RESULTS: All cell lines with the exception of PA-1 expressed EMA. Only MCF-7 was CEA-positive. MUC-1 was found in all cell lines apart from MDA-MB and SK-OV3. The highest expression of Her-2/neu was found in ZR-75/1 and SK-OV3. A491D and PA1 cells were CD19-negative, all other lines were positive. Only A491D and BT-20 had p53 accumulation. PR was found in 5 cell lines and ER in 6 cell lines.
CONCLUSION: The cell lines investigated express a different pattern of tumor markers. In consequence, a careful examination should be performed in order to find the "best fitting" cell line to a patient's tumor for a tumor-vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820346

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens.

Authors:  Cara C Bertozzi; Cheng-Yi Chang; Sonya Jairaj; Xiaochuan Shan; Jia Huang; Barbara L Weber; Christina S Chu; Richard G Carroll
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Mar-Apr       Impact factor: 2.416

Review 2.  Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.

Authors:  Katherine Stemke-Hale; Bryan Hennessy; Gordon B Mills; Rahul Mitra
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

Review 3.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 4.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

5.  In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells.

Authors:  Ekaterina I Galanzha; Evgeny V Shashkov; Thomas Kelly; Jin-Woo Kim; Lily Yang; Vladimir P Zharov
Journal:  Nat Nanotechnol       Date:  2009-11-15       Impact factor: 39.213

6.  Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma.

Authors:  Thomas G P Grunewald; Ulrike Kammerer; Michaela Kapp; Matthias Eck; Johannes Dietl; Elke Butt; Arnd Honig
Journal:  BMC Cancer       Date:  2007-10-23       Impact factor: 4.430

7.  Immunonanoshells for targeted photothermal ablation of tumor cells.

Authors:  Amanda R Lowery; André M Gobin; Emily S Day; Naomi J Halas; Jennifer L West
Journal:  Int J Nanomedicine       Date:  2006

8.  Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications.

Authors:  Anil Potti; Rachel C Hille; Michael Koch
Journal:  J Carcinog       Date:  2003-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.